Litcius/Paper detail

Medical nutrition therapy in patients with HIBCH and ECHS1 defects: Clinical and biochemical response to low valine diet

José E. Abdenur, Mary Sowa, Mariella Simon, Maija Steenari, Janette Skaar, Shaya S. Eftekharian, Richard Chang, Sacha Ferdinandusse, James Pitt

2020Molecular Genetics and Metabolism Reports29 citationsDOIOpen Access PDF

Abstract

3-hydroxyisobutyryl-CoA hydrolase (HIBCH) and short-chain enoyl-CoA hydratase (ECHS1 or crotonase) deficiencies are rare disorders in valine catabolism. HIBCH is responsible for the conversion of 3-OH-isobutyryl-CoA to 3-OH-isobutyric acid and its deficiency results in the buildup of 3-OH-isobutyric acid, which conjugates with free carnitine to 3-OH-isobutyryl carnitine (C4OH), which can be detected in acylcarnitine analysis. The ECHS1 enzyme is reversible which results in the buildup of methacrylyl-CoA, a highly reactive compound which conjugates with thiol groups and results in the accumulation of several toxic intermediates, including S-(2-carboxypropyl)-cysteamine, S-(2-carboxypropyl)-cysteine (SCPC) and its carnitine ester (SCPC-C) (Fig. 1) [1]. Open in a separate window Fig. 1 Pathway of valine catabolism. Solid lines denote the metabolic blocks. Solid arrows highlight accumulated metabolites. Dotted arrow shows inhibition of secondary pathways.

Topics & Concepts

CatabolismValineIsobutyric acidChemistryCarnitineInternal medicineCysteineEndocrinologyEnzymeBiochemistryThiolMedicineAmino acidMetabolism and Genetic DisordersDiet and metabolism studiesGenomics and Rare Diseases
Medical nutrition therapy in patients with HIBCH and ECHS1 defects: Clinical and biochemical response to low valine diet | Litcius